
Advertise on podcast: Oncology News Central Peer-Spectives
This podcast has
100 episodes
Language
EnglishPublisher
Oncololgy News CentralExplicit
No
Date created
2021/05/11
Latest episode
2026/10/02
Average duration
14 min.
Release period
21 days
Description
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Unlock Oncology News Central Peer-Spectives podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Social media
Check Oncology News Central Peer-Spectives social media presence
Podcast episodes
Check latest episodes from Oncology News Central Peer-Spectives podcast
How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR- Mutant NSCLC?
2026/10/02
Recording live at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from the Sylvester Comprehensive Cancer Center at the University of Miami, speaks with Wade Iams, MD, from Tennessee Oncology in Nashville, and Luis Raez, MD, from Memorial Cancer Institute in Miami, Forida, about selecting first-line combination therapy and managing amivantamab plus lazertinib in clinical practice.
Who Still Needs Monotherapy in EGFR- Mutant NSCLC
2026/09/24
Recording live at the 2026 World Conference on Lung Cancer in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from Sylvester Comprehensive Cancer Center, along with Misako Nagasaka, MD, PhD, from the University of California, Irvine School of Medicine, and Christine Lovly, MD, PhD, from City of Hope in Los Angeles, discuss first-line
EGFR-mutant NSCLC combinations, toxicity management, and PALOMA-2.
Is It Time for a New Type of Cancer Physician?
2026/08/21
The dramatic increase in cancer survivorship is introducing questions about the ability of physicians to meet patient needs. “Maybe we need to have a survivor cancer patient see a survivorship physician,” Robert Figlin, MD, discusses with Sunita Puri, MD.
What the “Tsunami” of Cancer Survivors Means for Oncologists
2026/07/16
Advances in cancer treatments have led to a rising “tsunami” of survivors, which has introduced a new set of challenges for oncologists. Saro H. Armenian, DO, MPH, discusses what changes are needed across oncology with Robert A. Figlin, MD.
“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation
2026/06/29
Amid the exciting advances at ASCO 2026, there came a “sobering moment” regarding the U.S.’s role as a cancer clinical trial leader, says Robert A. Winn, MD. He discusses what this means for cancer centers going forward with Robert A. Figlin, MD.
“A Lot More Asymptomatic Cancer Out There”: Major MCED Trial Hints at Complicated Future
2026/06/23
The prospective randomized NHS-Galleri multicancer early detection trial didn’t meet its primary endpoint, but it did uncover a lot more early-stage cancers than predicted. Eric Klein, MD, and Robert Figlin, MD, talk about what the data reveal about cancer biology and for screening programs.
“The Ever-Shifting and Chaotic” State of CLL Care: What New Data Mean for Practice
2026/06/23
Data presented at the 2026 American Society of Clinical Oncology Annual Meeting add to the “ever-shifting and chaotic space” that is CLL care, says Matthew Lunning, DO. He discusses how new findings are affecting practice with Robert A. Figlin, MD.
How “Drastically Better” Treatments for Some Colorectal Cancers Are Changing Care
2026/06/17
New treatments for patients with microsatellite instability–high colorectal cancer are drastically changing outcomes. Nicholas James Hornstein, MD, PhD, discusses recent advances and key findings from the 2026 American Society of Clinical Oncology Annual Meeting with Carolina Bernabe Ramirez, MD
“Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care
2026/04/29
In the wake of recent key data about ESR1-mutated metastatic breast cancer, treatment decisions have become more complicated. “In current clinical practice, this is not a straightforward decision,”
Marla Lipsyc-Sharf, MD, explains to Robert A. Figlin, MD.
New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
2026/04/21
“In breast cancer now, all of our treatment for hormone receptor–positive metastatic
disease is a bit of a moving target because of new therapies that are available,”
explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women’s
Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte,
California. She discusses the “ever-changing” landscape involving the PI3
kinase/AKT/mTOR pathway with Robert A. Figlin, MD, the Steven Spielberg Family
Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. Dr. Rugo details
key considerations that she uses for decision making in practice. “And I think we just
want to be cautious about toxicity for these patients and really know that we’re
benefiting them, rather than using up treatments,” she explains.
Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
2026/04/17
As the management of patients with ESR1-mutated metastatic breast cancer evolves,
various questions have emerged in clinical practice. “It's a complex situation,” explains
Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers
Program director at the City of Hope Comprehensive Cancer Center in Duarte,
California. She discusses how recent advances have changed treatment decisions with
Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at
Cedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today we
just have single-agent oral SERDs, and people like to give combinations,” Dr. Rugo
notes. But what combinations to give and when remains unclear. “I think how we're
going to decide is that we're going to wait and see what's approved and then look at
patients to try and figure out what to do,” she offers.
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
2026/04/02
How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice? Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, speaks with Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer program at AdventHealth Cancer Institute and associate professor of medicine at the University of Central Florida in Orlando, about how to best use oral selective estrogen receptor degraders. “And the big question is ‘Can we use SERDs in combination, or are SERDs effective in patients without an ESR1 mutation?’ Can we go outside the current approved guidelines? And I think that’s the biggest question that everyone is asking today,” notes Dr. Mchayleh.
Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
2025/12/18
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He
describes the options available for prophylaxis and how he treats the toxicities that do arise.
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
2025/12/18
Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a longevity perspective,” explains Sid Devarakonda, MD, director of thoracic medical oncology at Swedish Cancer Institute in Seattle and clinical associate professor at Washington State University. He speaks with Aakash Desai, MD, MPH, associate director of the Phase 1 and Precision Oncology program at the University of Alabama at Birmingham, about how CNS metastases inform choices between regimens. Dr. Devarakonda also discusses how the recent U.S. Food and Drug Administration approval of subcutaneous amivantamab (Rybrevant Faspro) may change his approach. “[Y]ou still need to be comfortable managing some of the toxicities that still persist, even with the subcutaneous formulation, but it's terribly convenient from a practical perspective,” he notes.
Dr. Desai and Dr. Devarakonda reported various financial relationships.
Second-Line Options in EGFR-Mutated NSCLC: What’s the Right Sequence?
2025/12/18
Podcast reviews
Read Oncology News Central Peer-Spectives podcast reviews
Podcast sponsorship advertising
Start advertising on Oncology News Central Peer-Spectives relevant audience podcasts
You may also like to advertise on these Podcasts

4.7278962000
The Matt Walsh Show
The Daily Wire

4.959962000
Legal AF by MeidasTouch
MeidasTouch Network

4.7292842000
The Michael Knowles Show
The Daily Wire

4.897081456
The Graham Allen Show
Graham Allen

4.930902000
The Quote of the Day Show | Daily Motivational Talks
Sean Croxton

4.7106622000
FantasyPros - Fantasy Football Podcast
iHeartPodcasts

4.6253972000
The Glenn Beck Program
Mercury Radio Arts

4.8224901808
The Andrew Klavan Show
The Daily Wire

4.6652782197
The Charlie Kirk Show
Charlie Kirk

4.6432911273
Verdict with Ted Cruz
Premiere Networks
